UNSPSC 51291805: Eclanamine maleate

This classification denotes an antidepressant agent with the molecular formula C16H22CL2N2O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J2C169J769. The term eclanamine maleate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule eclanamine maleate under HS 29242995 and SITC 51479. As of Q4 2014, ECLANAMINE MALEATE remains US FDA's Preferred Term for this commodity. Eclanamine maleate bears US NLM identifiers UMLS ID C0957739 and NCI Concept Code C75171.

SMILES: CCC(=O)N(C1CCC(C(C1)CL)CL)[C@@H]2CCC[C@H]2N(C)C.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51291805 Eclanamine maleate is a Commodity code that represents a specific pharmaceutical active ingredient, yet the recent state and local solicitations tagged under it diverge significantly from this narrow product scope. The opportunities instead reflect state and local procurement of finished pharmaceutical products and pharmacy benefit program services—including naloxone and drug deactivation systems for community health, direct-to-manufacturer prescription fulfillment models, and multi-source generic pharmaceuticals distributed through authorized wholesalers. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances serving multiple states and jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The code shows little cohesion around the nominal active ingredient; rather, it reflects broader pharmaceutical procurement activity at the state and local level, where health departments, cooperative purchasing bodies, and state agencies are consolidating demand for finished medications and pharmacy services.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (response due July 26, 2023) for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, requiring vendors to include shipping and delivery costs, carry workers' compensation and liability insurance, and comply with E-Verify and drug-free workplace certification. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capability information on direct-to-manufacturer prescription programs for self-insured employee health plans and state agencies, seeking vendors experienced in negotiated net pricing models and value-based agreements outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026 and evaluation weighted heavily on price competitiveness (75 percent). The code shows material recent activity but lacks product-line consistency with its nominal chemical definition.